Neuland Laboratories has reported several key decisions following its recent board meeting. The company has approved a final dividend of ₹34 per equity share, representing a 340% return on a face value of ₹10 each for the fiscal year 2025-26. This dividend is set for distribution on or after five days from its declaration at the upcoming 42nd Annual General Meeting (AGM).
In addition to the dividend announcement, Neuland Laboratories has appointed Dr. Mauricio Futran as an Additional Director. Dr. Futran will serve as a Non-Executive Non-Independent Director, effective from 12 May 2026. His appointment follows the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval at the forthcoming AGM.
The company has also scheduled its 42nd AGM for 4 August 2026. The record date for determining shareholders eligible to receive the final dividend has been set for 24 July 2026.
Furthermore, Neuland Laboratories plans to enhance the capacity of its Unit 1 at Bonthapally Village, Telangana. The expansion will increase the unit’s capacity by 120.5 KL, with the project expected to be completed within 12 to 18 months. The investment required for this expansion is estimated at ₹143.4 crores, which will be financed through internal accruals and borrowings. This move aims to meet the growing demand from customers.
The board meeting where these decisions were made commenced at 2:15 p.m. and concluded at 3:45 p.m.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).